Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Overview of attention for article published in Lancet Neurology, April 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 39 news outlets
blogs: 1 blog
twitter: 12 X users

patent: 1 patent
guideline: 1 clinical guideline source

Readers on

mendeley: 177 Mendeley

So far, Altmetric has seen 12 X posts from 12 X users, with an upper bound of 90,414 followers.

RT @thmonk_pf: デュシェンヌ型筋ジストロフィー（DMD）に対するギビノスタット（HDAC阻害薬）の有効性と安全性を検討した第III相試験（EPIDYS試験）の結果ギビノスタットは、DMD患者の運動機能低下を抑制する https://t.co/TVcheyUxay

デュシェンヌ型筋ジストロフィー（DMD）に対するギビノスタット（HDAC阻害薬）の有効性と安全性を検討した第III相試験（EPIDYS試験）の結果ギビノスタットは、DMD患者の運動機能低下を抑制する https://t.co/TVcheyUxay

FDA ha approvato givinostat, un HDAC inhibitor, per la distrofia muscolare di Duchenne. I risultati non sono potentissimi ma, a livello motorio, i pazienti sotto trattamento hanno migliorato alcuni aspetti motori. Step by step. https://t.co/0Qfaim27wD

ICYMI in our April issue: results from the EPIDYS trial of givinostat for boys with Duchenne muscular dystrophy, from Eugenio Mercuri and colleagues https://t.co/YnWtgCKYFy

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.